The present study is aimed to investigate the treatment benefits of a combination of dietary supplements quercetin, curcumin and vitamin D3 as add-on therapy to the routine care for early mild symptoms of COVID-19 infection in outpatients setting.
There is currently no specific early-stage therapeutic treatment available for COVID-19.
Dietary supplements curcumin, quercetin and vitamin D3 have shown strong antioxidant,
anti-inflammatory/immunomodulatory and broad-spectrum antiviral effects. The present study is
focused to test the combination of oral curcumin, quercetin and vitamin D3 supplements as
complementary therapy for outpatients with mild to moderate symptoms of COVID-19 infection.
Dietary Supplement: Complementary therapy
A daily supplementation of 168 mg curcumin, 260 mg quercetin and 360 IU of vitamin D3 (cholecalciferol) for 14-days
Drug: Standard of care
This arm will receive standard of care as per the hospital guidelines
Inclusion Criteria:
- Patients must be 18 years of age or older, of either gender
- Patients must be tested positive for SARS-CoV-2 by RT-PCR within 72 hours prior to
enrolment
- Patients must exhibit typical symptoms of COVID-19 disease at screening such as fever,
fatigue, a dry and contagious cough, loss of appetite, body aches, shortness of
breath, mucus or phlegm, sore throat, headache, chills, sometimes with shaking, loss
of smell or taste, congestion or runny nose, nausea, or vomiting, diarrhea, muscular
pain etc.
- Patients must be in the early stage of COVID-19 disease who do not require
hospitalization at the time of screening
- Patients must be under the care of a Physician for diagnosis of COVID-19
- Patients who have signed informed consent
Exclusion Criteria:
- Patients with proven hypersensitivity or allergic reaction to quercetin or curcumin
- Patients with known chronic kidney disease with estimated creatinine clearance < 50
mL/minute or need for dialysis
- Patients who are severely hypotensive defined as needing hemodynamic pressors to
maintain blood pressure
- Patients taking anticoagulant/antiplatelet drugs such as Coumarine, Heparine, Aspirin,
Clopidrogel, dalteparin, enoxaparin, ticlopidine and warparin.
- Patients with gallstone obstruction
- Hypothyroid suffering patients
- Patients with moderate or severe thrombocytopenia (platelet count <100 ×10⁹/L);
- Pregnant patients
Liaquat University Hospital
Jāmshoro, Sindh, Pakistan